Patient P-02582

Synthetic patientMETA-24 · Day 177 · 55–64 · M · baseline S14Open companion preview

Therapy response

Stable

Tolerance

Unstable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 75 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 80 ME-01 recommended — Monitoring Escalation ME-01
Day 81 Patient accepted — Started ME-01 in the companion
Day 84 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 75.

Primary contributors, last 14 days

Toxicity+9
Inflammatory activity+8
GI instability-4
Nutritional resilience+3

What helped?

Monitoring Escalation ME-01Day 80
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
88% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 70
- WearableHRV 15 ms, trending down
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 22/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 90 bpm
- Wearable1,624 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓20
- Daily logGI symptom score 70 and rising
Drug metabolism and exposure ↑20
- BloodToxicity index 64

DNA

Fictional pharmacogenomic panel

IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
MTHFR C677T
Reduced folate turnover

Microbiome

Shannon diversity 3 · butyrate capacity 22/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumLow
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 18 ms
Sleep: 6.7 h
Steps: 1,779
Resting HR: 89 bpm

Daily log: GI score 70, nutritional resilience 30, adherence 45.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02297	53%	S02	NP-02	improved	49
P-02505	53%	S14	NP-02	improved	45
P-02057	52%	S14	GI-04	improved	47
P-02610	50%	S14	NP-02	no change	42
P-02146	48%	S14	ME-01	improved	33
P-02542	48%	S14	NP-02	improved	44
P-02594	48%	S20	—	—	45
P-02648	48%	S14	SC-12	improved	47
P-02372	47%	S14	ME-01	improved	53
P-02643	47%	S14	SC-12	improved	46
P-02320	46%	S14	NP-02	improved	50
P-02348	46%	S14	GI-04	improved	49